New Year Bumper Sale @ Rs. 1 X
Monticope Suspension 30ml is a prescription drug, available for use as Syrup. Secondary and off-label uses of Monticope Suspension 30ml have also been mentioned below.
The right dosage of Monticope Suspension 30ml depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
The most common side effects of Monticope Suspension 30ml are Headache, Stomach ache, Joint pain. These side effects of Monticope Suspension 30ml are usually temporary and subside with the completion of treatment. If, however, they worsen or do not go away, please speak with your physician.
Monticope Suspension 30ml's effect during pregnancy is Severe and Severe while nursing. Further, the section on Monticope Suspension 30ml related warnings talks about Monticope Suspension 30ml's effects on the liver, heart and kidney.
Monticope Suspension 30ml is not recommended if you suffer from certain medical conditions as it can have adverse effects. Liver Disease are examples of such conditions.
Additionally, Monticope Suspension 30ml may also adversely react with other medicines. A complete list of these interactions is given below.
You should also be aware that Monticope Suspension 30ml is not safe while driving, and is not addiction.
Monticope Suspension 30ml is used to treat the following -
Main Benefits
Other Benefits
Based on research, the following side effects have been observed when Monticope Suspension 30ml is used -
Common
Monticope Suspension 30ml should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Monticope Suspension 30ml unless your doctor advises you to do so -
Is this Monticope Suspension 30ml habit forming or addictive?
Monticope Suspension 30ml does not cause addiction.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xyzal® (levocetirizine dihydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 164,167
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
Product Index [Internet]: MONTAIR LC & MONTAIR LC KID DT / Syrup (Montelukast sodium + Levocetirizine dihydrochloride ). Ciplamed
Highlights of Prescribing Information [Internet]: XYZAL® (levocetirizine dihydrochloride) tablets . Initial U.S. Approval: 19952007
Smpc [Internet]: montelukast sodium. Aurobindo Pharma
Package leaflet Information for the patient [Internet]: Xyzal 0.5 mg/ml oral solution. UCB Pharma Ltd